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Impact of academic detailing on clinical pharmacy specialist involvement in medication assisted
treatment for opioid use disorder in a primary care setting

Health & Services

Lindsey M. Bartos, PharmD, Kristin A. Tallman, PharmD, BCPS, BCACP, and Dara L. Johnson, PharmD, BCPP, BCACP

Purpose

Discussion

To identify and address common barriers to Clinical
Pharmacy Specialist (CPS) involvement in medication
assisted treatment (MAT) for opioid use disorder (OUD)
through academic detailing interventions to improve CPS
comfort level with MAT for OUD, and increase the number of
patients with a CPS involved in the treatment of their OUD.

Respondents

Background
• Opioid prescribing and overdose deaths began
increasing in the 1990s, and continued for decades,
reaching a 6-fold increase between 1999 to 2017 1,2
• MAT is a method of treating substance use disorders
using a combination of counseling, behavioral therapy,
and FDA-approved medications1
• The use of buprenorphine in MAT for the treatment of
OUD has been shown to reduce the use of opiates,
cravings for opiates, and risk of all-cause and opioidrelated mortality, but remains under-utilized in primary
care settings3,4
• CPSs have been shown to improve health outcomes,
increase cost-effectiveness, and improve the quality of
health care through collaborative, evidence based
patient care services for chronic disease states5
• Despite the potential to improve outcomes through
collaborate practice, CPS involvement in the treatment
of OUD remains limited5
• The current involvement and perceived barriers among
the 26 CPS within a large medical group are unknown.
Identifying and addressing these barriers through
academic detailing will encourage their involvement in
MAT for OUD

Labs on
admission:
Objectives

• Identify and describe the most common barriers to CPS
involvement in MAT for OUD
• Assess the impact of academic detailing on clinical
pharmacy specialists’ (CPS) comfort level with being
involved in the care of patients undergoing MAT for OUD
• Assess the hypothesis that academic detailing will lead to
an increase in the number of patients with a CPS involved
in the treatment of their OUD

Methodology
• Institutional Review Board (IRB)-approved
• Comparison of pre and post survey responses following
an academic detailing intervention (two 45 minute
required sessions)
• Academic detailing learning objectives:
• Review the use of buprenorphine for OUD
• Describe medications for withdrawal symptom
management
• Identify resources to aid in MAT
• Apply principles of treatment with buprenorphine
to patient cases
• Inclusion criteria: CPSs at PMG primary care clinics in
Oregon and SW Washington
• Exclusion criteria: none
• Primary outcome:
• CPS comfort with and knowledge of
buprenorphine in MAT for OUD
• Secondary outcome:
• Number of patients with a CPS involved in the
care of their OUD
• The primary outcome was analyzed using a Wilcoxonrank-sum test with a two sided p-value

Primary Outcome Results
Table 1. Survey Respondents
Respondents
Pre-survey, No.
Post-survey, No.
Years in Practice
0-2 years, No. (%)
3-5 years, No. (%)
6-10 years, No. (%)
10+ years, No. (%)

Table 2. Prescribing Habits
Involvement in MAT
Currently involved, No. (%)
Inductions only, No. (%)
Inductions and maintenance, No.
(%)
Clinics with ≥1 X-waivered
provider, No. (%)
PMG buprenorphine
prescriptions, No.

19
20
7 (36.84)
7 (36.84)
3 (15.79)
2 (10.53)

4 (21.05)
2 (10.53)
2 (10.53)
22 (62.86)
1,038

X-waiver: DATA2000 waiver

Figure 1. Barriers
7.69% 1.92%

Lack of time

23.08%

7.69%

Lack of X-waivered providers in clinic

• The three most common barriers identified were a lack of
time (23.08%), lack of X-waivered providers in clinic
(23.08%), and lack of knowledge (21.15%) (Figure 1)
• The factor most commonly rated as the #1 barrier was a
lack of X-waivered providers in clinic (38.89%)
• Pre and post survey results are listed in Table 3.
• All responses were statistically significantly improved
following the academic detailing intervention, with the
exception of two questions regarding medication use for
withdrawal symptoms and the role of a CPS in MAT for
OUD (p>0.05)

Other
Challenging patient population
23.08%

Barriers

Comfort, Knowledge, and Beliefs

Lack of knowledge regarding MAT
15.38%

• 19 participants responded to the pre-survey and 20
responded to the post survey
• 4/19 (21.05%) respondents to the pre-survey were
currently active in MAT. Of these, 3 indicated they were
involved in MAT for 1-5 patients annually, and 1 indicated
they are involved with MAT for 20+ patients annually.
Respondents’ demographics are included in Table 1
• There was no change in the number of CPSs involved in
MAT in the time between the two surveys

Low volume of patients needing MAT
Provider unwillingness to involve clinical pharmacy

21.15%

Study Limitations
Table 3. Comfort, Knowledge, and Beliefs
Survey Question
I feel comfortable explaining
the role of a Clinical
Pharmacist in MAT to my
providers.
I feel comfortable managing
patients on buprenorphine
for MAT.
I feel confident in my ability
to conduct a buprenorphine
induction.
I feel confident in my ability
to treat patients with
buprenorphine during the
maintenance phase.
I feel confident in my
knowledge of the
medications used to treat
withdrawal symptoms .
I know where to find
workflows /resources to
assist in treating patients on
MAT.
I understand the role of a
Clinical Pharmacy Specialist
in MAT in primary care.
My level of knowledge
about the use of
medications for MAT is
sufficient.

Pre

SA

A

N

D

SD

5.26%

26.32%

31.58%

31.58%

5.26%

P value
0.004

Post

10%

70%

20%

0%

0%

Pre

5.26%

10.53%

31.58%

36.84%

15.79%

• Data collected through the use of surveys is susceptible to
response bias
• Academic detailing interventions were specific to
respondent’s identified barriers and may not be applicable
to every primary care practice site
• CPS involvement in MAT is dependent on provider’s ability
to prescribe buprenorphine
• Respondents to the pre-survey and post-survey were
unable to be matched for analysis

0.012
Post
Pre

5%
5.26%

40%
10.53%

45%
15.79%

5%
42.11%

5%

Conclusions

26.32%
0.012

Post

0%

35%

40%

25%

0%

Pre

5.26%

10.53%

21.05%

52.63%

10.53%
0.001

Post

15%

45%

35%

5%

0%

Pre

5.26%

42.11%

21.05%

31.58%

0%
0.250

Post

5%

55%

35%

5%

0%

Pre

15.79%

47.37%

21.05%

15.79%

0%
0.034

Post
Pre

30%
5.26%

70%
52.63%

0%
5.26%

0%
36.84%

0%

Next Steps

0%
0.051

Post

10%

80%

10%

0%

0%

Pre

5.26%

10.53%

26.32%

47.37%

10.53%
0.011

Post

0%

45%

40%

15%

• This study was conducted to identify and address barriers
to determine if this increases CPS involvement in MAT
• Most CPSs within PMG are not currently involved in the
use of buprenorphine in MAT for OUD, due to a
combination of different barriers
• Academic detailing can significantly impact CPSs’ comfort
with MAT for OUD, including:
• The use of buprenorphine in induction and
maintenance
• Talking to providers about the role of a CPS in
MAT for OUD
• Finding workflows and resources to assist in the
use of buprenorphine for MAT

0%

CPS involvement in MAT will be re-assessed through the use
of a survey or electronic database tracking in June 2020, and
compared to involvement at the time of the pre-survey
before the academic detailing intervention.
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